Cardiac Myxoma: Diagnosis and Management
Diagnosis
Transthoracic echocardiography (TTE) is the first-line diagnostic test for suspected cardiac myxoma, with transesophageal echocardiography (TEE) providing superior sensitivity (90-96% accuracy) when TTE is inconclusive or for surgical planning. 1, 2, 3
Key Diagnostic Features
Epidemiology and Location: Cardiac myxomas are the most common primary cardiac tumors, occurring in 0.02% of autopsy series, with 75% arising in the left atrium attached to the interatrial septum near the fossa ovalis 1, 4, 2
Clinical Presentation Triad 1, 4:
- Cardiac symptoms (73%): Dyspnea, heart failure symptoms, syncope from mechanical mitral valve obstruction
- Embolic events (25-27%): Stroke is the presenting symptom in up to 50% of cases
- Constitutional symptoms (30%): Fever, weight loss, elevated inflammatory markers
Physical Examination: A mid-diastolic rumbling murmur at the apex (present in 53.5% of patients) that mimics mitral stenosis but lacks the opening snap characteristic of true valvular disease; perform dynamic auscultation with positional changes as murmurs may be intermittent 1
Imaging Algorithm
- Initial TTE for all suspected cases 5
- TEE when TTE is inconclusive, for younger patients with cryptogenic stroke, or for detailed pre-operative planning 5, 1, 3
- Cardiac MRI or CT for additional tumor characterization, especially for atypical locations or when assessing embolic risk based on surface morphology 5, 1, 6
Critical Diagnostic Pitfall
Do NOT perform endomyocardial biopsy on typical myxomas because right-sided myxomas can embolize to the lungs with manipulation, and the diagnosis can be established non-invasively 5
Management
Urgent surgical excision is the only definitive treatment and should be performed as soon as possible after diagnosis to prevent life-threatening complications including stroke, sudden death, and cardiac obstruction. 1, 4, 6
Surgical Indications (Class I-IIa Recommendations)
- All symptomatic left atrial myxomas require immediate surgical resection 1, 4
- Asymptomatic myxomas should also undergo resection given the 25% overall embolism rate and unpredictable risk of sudden death 1, 6
- Cryptogenic stroke patients with identified left atrial myxoma benefit from resection to reduce recurrent stroke risk (Class IIa, Level of Evidence C-LD) 6
Surgical Approach
- Median sternotomy remains the standard approach with excellent outcomes, low mortality, and complete tumor visualization 7
- Complete excision with adequate atrial septal margin is essential to prevent recurrence (occurs in 1-5% of sporadic cases, higher in Carney complex) 1, 8
- Minimally invasive or robotic-assisted surgery may be considered in select cases but requires specialized expertise and is associated with longer operative times 7
Peri-operative Echocardiography
- Intraoperative TEE is mandatory to assess mitral valve anatomy, guide complete resection, and detect complications such as residual tumor or iatrogenic ventricular septal defect 5
- Post-operative TTE within 3-6 months to evaluate surgical results 5
Critical Management Pitfalls
Anticoagulation or antiplatelet therapy alone is inadequate and does not prevent embolic complications or relieve mechanical obstruction—these should never be used as definitive therapy. 1, 4, 6
Do NOT perform pericardiocentesis if pericardial effusion is present, as this may worsen hemodynamics 4
Risk Stratification
Villous or papillary surface morphology on imaging indicates markedly higher embolic potential and reinforces the urgency for immediate surgical intervention. 1, 6
- Larger myxomas correlate with cardiac symptoms and hemodynamic compromise 9
- Smaller myxomas present more frequently with embolic phenomena 9
- Right-sided tumors require evaluation for patent foramen ovale due to paradoxical embolism risk 1, 6
Long-term Follow-up
- Periodic echocardiography to monitor for recurrence, especially in patients with Carney complex (up to 10% of cases) who have younger age at presentation, multiple/atypical locations, and high recurrence risk 10, 8
- Genetic testing should be considered in young patients (<40 years), those with multiple myxomas, or family history suggestive of Carney complex 10, 8
Special Populations
Children and patients with Carney complex require heightened surveillance as they present at younger ages (mean 9-10 years in children), have atypical tumor locations (right atrium, ventricles), and carry significantly higher recurrence rates 8